Skip to content

Clinical trials

Phase 4 Liver Cirrhosis trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Liver Cirrhosis Phase: Phase 4 Clear all

88 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20032
20064
20073
20082
20091
20104
20117
20123
20138
20158
20161
20177
20181
20194
20205
20216
20224
20235
202410
20251
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed33
Unknown status29
Recruiting8
Terminated6
Active, not recruiting5
Not yet recruiting3
Withdrawn3
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Beijing Friendship Hospital4
Kafrelsheikh University4
Shanghai Zhongshan Hospital4
Taipei Veterans General Hospital, Taiwan3
Aristotle University Of Thessaloniki2
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau2
Hospital Clinic of Barcelona2
Hvidovre University Hospital2
King's College Hospital NHS Trust2
Weill Medical College of Cornell University2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Liver Cirrhosis88
Fibrosis11
Hypertension, Portal11
Hepatic Encephalopathy7
Hepatitis B, Chronic7
Hepatitis B6
Carcinoma, Hepatocellular4
Diabetes Mellitus, Type 24
Esophageal and Gastric Varices4
Gastrointestinal Hemorrhage4

Trials

Showing 51 to 75 of 88. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.